SEC Tracker
Get the app

Aibotics AIBT

Aibotics Q2 FY25: revenue $0

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Aibotics reported for Q2 FY25, the quarter ended Jun 30, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$0Against $0 in Q2 FY2410-Q income statement, on EDGAR
  2. Net income−$486KAgainst −$471K in Q2 FY2410-Q income statement, on EDGAR
  3. Cash and cash equivalents$242K−13% from $280K in Q2 FY2410-Q balance sheet, on EDGAR
  4. Cash from operations−$165KAgainst −$91K in Q2 FY2410-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Aibotics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2833 and related industry codes: the same peer list as the financial tables.

  1. Agentix AGTX public float $1M, Sep 30, 2025
  2. Galera Therapeutics GRTX public float $2M, Jun 30, 2025
  3. ProtoKinetix PKTX public float $2M, Jun 30, 2026
  4. Evofem Biosciences EVFM public float $1M, Jun 30, 2025
  5. Regen BioPharma RGBP public float $1M, Mar 31, 2025, over 18 months old